Asset Details

MbrlCatalogueTitleDetail

Do you wish to reserve the book?

Fixed-Duration Acalabrutinib Combinations in Untreated Chronic Lymphocytic Leukemia

by Seymour, John F. , Skarbnik, Alan , Eom, Ki-Seong , Šimkovič, Martin , de Borja, Marianne , Wach, Malgorzata , Kater, Arnon Philip , Munugalavadla, Veerendra , Illes, Arpad , Jurczak, Wojciech , Pavlovsky, Miguel Arturo , Miller, Kara , Brown, Jennifer R. , Aw, Andrew , Lysak, Daniel , Owen, Carolyn , Tedeschi, Alessandra , Eichhorst, Barbara , Ghia, Paolo , Yu, Ting

in Adult / Aged / Aged, 80 and over / Antibodies, Monoclonal, Humanized - administration & dosage / Antibodies, Monoclonal, Humanized - adverse effects / Antineoplastic Combined Chemotherapy Protocols - administration & dosage / Antineoplastic Combined Chemotherapy Protocols - adverse effects / Bendamustine Hydrochloride - administration & dosage / Benzamides - administration & dosage / Benzamides - adverse effects / Bone marrow / Bridged Bicyclo Compounds, Heterocyclic - administration & dosage / Bridged Bicyclo Compounds, Heterocyclic - adverse effects / Cancer therapies / Chemotherapy / Chronic lymphocytic leukemia / Coronaviruses / COVID-19 / Cyclophosphamide / Cyclophosphamide - administration & dosage / Female / Flow cytometry / Fludarabine / Gene deletion / Hematology / Humans / Immunotherapy / Intention to Treat Analysis / Kaplan-Meier Estimate / Leukemia / Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy / Leukemia, Lymphocytic, Chronic, B-Cell - genetics / Leukemia, Lymphocytic, Chronic, B-Cell - mortality / Lymphoma / Male / Middle Aged / Monoclonal antibodies / Neutropenia / Oncology / Progression-Free Survival / Pyrazines - administration & dosage / Pyrazines - adverse effects / Rituximab / Rituximab - administration & dosage / Rituximab - adverse effects / Sulfonamides - administration & dosage / Sulfonamides - adverse effects / Survival / Targeted cancer therapy / Treatment Outcome / Treatments in Oncology / Vidarabine - administration & dosage / Vidarabine - adverse effects / Vidarabine - analogs & derivatives

2025

Yes Please

Hey, we have placed the reservation for you!

By the way, why not check out events that you can attend while you pick your title.

Oops! Something went wrong.

Looks like we were not able to place the reservation. Kindly try again later.

Are you sure you want to remove the book from the shelf?

Fixed-Duration Acalabrutinib Combinations in Untreated Chronic Lymphocytic Leukemia

2025

Confirm

Do you wish to request the book?

Fixed-Duration Acalabrutinib Combinations in Untreated Chronic Lymphocytic Leukemia

2025

Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy

How would you like to get it?

Submit

We have requested the book for you!

Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.

Oops! Something went wrong.

Looks like we were not able to place your request. Kindly try again later.

Journal Article

Fixed-Duration Acalabrutinib Combinations in Untreated Chronic Lymphocytic Leukemia

Seymour, John F.,

Skarbnik, Alan,

Eom, Ki-Seong,

Šimkovič, Martin,

de Borja, Marianne,

Wach, Malgorzata,

Kater, Arnon Philip,

Munugalavadla, Veerendra,

Illes, Arpad,

Jurczak, Wojciech,

Pavlovsky, Miguel Arturo,

Miller, Kara,

Brown, Jennifer R.,

Aw, Andrew,

Lysak, Daniel,

Owen, Carolyn,

Tedeschi, Alessandra,

Eichhorst, Barbara,

Ghia, Paolo,

Yu, Ting

2025

Overview

Among previously untreated patients with chronic lymphocytic leukemia, 3-year progression-free survival was 76.5% with acalabrutinib–venetoclax, 83.1% with acalabrutinib–venetoclax–obinutuzumab, and 66.5% with chemoimmunotherapy.

Share this book

Add to My Shelf

Publisher

Massachusetts Medical Society

Subject

Adult

/ Aged

/ Aged, 80 and over

/ Antibodies, Monoclonal, Humanized - administration & dosage

/ Antibodies, Monoclonal, Humanized - adverse effects

/ Antineoplastic Combined Chemotherapy Protocols - administration & dosage

/ Antineoplastic Combined Chemotherapy Protocols - adverse effects